{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T21:50:09Z","timestamp":1785880209136,"version":"3.56.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP25K19095"],"award-info":[{"award-number":["JP25K19095"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.cllc.2026.05.010","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T05:33:16Z","timestamp":1780119196000},"page":"43-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Durvalumab After Chemoradiotherapy for Locally Advanced NSCLC: A Real-World Analysis Using a Nationwide Claims Database in Japan"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7354-4063","authenticated-orcid":false,"given":"Kazuya","family":"Takeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaya","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rei","family":"Umezawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsaku","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Jingu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2026.05.010_bib0001","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.05.010_bib0002","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.05.010_bib0003","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jtho.2020.12.015","article-title":"Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC\u2014an update from the PACIFIC trial","volume":"16","author":"Faivre-Finn","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2026.05.010_bib0004","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2026.05.010_bib0005","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jtho.2022.10.003","article-title":"Treatment characteristics and real-world progression-free survival in patients with unresectable stage III NSCLC who received durvalumab after chemoradiotherapy: findings from the PACIFIC-R study","volume":"18","author":"Girard","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2026.05.010_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103464","article-title":"Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R","volume":"9","author":"Filippi","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.cllc.2026.05.010_bib0007","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.lungcan.2021.08.019","article-title":"Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005\/CRIMSON)","volume":"161","author":"Saito","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2026.05.010_bib0008","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.jtho.2023.04.008","article-title":"Korean real-world data on patients with unresectable stage III NSCLC treated with durvalumab after chemoradiotherapy: PACIFIC-KR","volume":"18","author":"Park","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2026.05.010_bib0009","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jtho.2025.08.010","article-title":"Long-term safety and effectiveness of durvalumab in unresectable stage III NSCLC in Japan: a multicenter prospective study (AYAME)","volume":"21","author":"Kenmotsu","year":"2026","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2026.05.010_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1647385","article-title":"Durvalumab following definitive chemoradiotherapy among patients with stage III NSCLC in the Thai population: a real-world, multicenter observational study","volume":"15","author":"Sitthideatphaiboon","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.cllc.2026.05.010_bib0011","article-title":"Symptomatic pneumonitis with durvalumab after concurrent chemoradiotherapy in unresectable stage III NSCLC","volume":"5","author":"Vansteenkiste","year":"2024","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.cllc.2026.05.010_bib0012","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejca.2020.10.008","article-title":"Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: a real-world multicentre study","volume":"142","author":"Desilets","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cllc.2026.05.010_bib0013","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.lungcan.2022.06.003","article-title":"Dosimetric predictors of pneumonitis in locally advanced non-small cell lung cancer patients treated with chemoradiation followed by durvalumab","volume":"170","author":"Gao","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2026.05.010_bib0014","doi-asserted-by":"crossref","first-page":"6427","DOI":"10.21037\/jtd-22-1604","article-title":"A real-world study of pneumonitis in non-small cell lung cancer patients receiving durvalumab following concurrent chemoradiation","volume":"15","author":"Akkad","year":"2023","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.cllc.2026.05.010_bib0015","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/bjr\/tqaf133","article-title":"Pneumonitis after chemoradiation followed by durvalumab for locally advanced lung cancer: predictors and effect on survival","volume":"98","author":"Appel","year":"2025","journal-title":"Br J Radiol"},{"key":"10.1016\/j.cllc.2026.05.010_bib0016","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.cllc.2021.01.017","article-title":"Incidence and risk factors of symptomatic radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent chemoradiotherapy and consolidation durvalumab","volume":"22","author":"Shintani","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2026.05.010_bib0017","article-title":"Pneumonitis during durvalumab consolidation therapy affects survival in stage III NSCLC","volume":"4","author":"Kinehara","year":"2023","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.cllc.2026.05.010_bib0018","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1111\/cas.16094","article-title":"Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: a real-world study (HOT2101)","volume":"115","author":"Tsuji","year":"2024","journal-title":"Cancer Sci"},{"key":"10.1016\/j.cllc.2026.05.010_bib0019","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.2217\/fon-2023-0117","article-title":"Durvalumab real-world treatment patterns and outcomes in patients with stage III non-small-cell lung cancer treated in a US community setting","volume":"19","author":"Waterhouse","year":"2023","journal-title":"Future Oncol"},{"key":"10.1016\/j.cllc.2026.05.010_bib0020","doi-asserted-by":"crossref","first-page":"e382","DOI":"10.1016\/j.cllc.2025.04.012","article-title":"Common medical comorbidities influence pneumonitis risk after chemoradiotherapy and durvalumab maintenance in stage III non-small cell lung cancer","volume":"26","author":"Ohaegbulam","year":"2025","journal-title":"Clin Lung Cancer"},{"issue":"2","key":"10.1016\/j.cllc.2026.05.010_bib0021","first-page":"190","article-title":"Prevalence of noncommunicable diseases in Japan using a newly developed administrative claims database covering young, middle-aged, and elderly people","volume":"5","author":"Okada","year":"2022","journal-title":"JMA J"},{"key":"10.1016\/j.cllc.2026.05.010_bib0022","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.cllc.2026.05.010_bib0023","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.cllc.2026.05.010_bib0024","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.annepidem.2007.03.011","article-title":"A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients","volume":"17","author":"Klabunde","year":"2007","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.cllc.2026.05.010_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108583","article-title":"Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT \u2192 durvalumab in Canada: the RELEVANCE study","volume":"204","author":"Wheatley-Price","year":"2025","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2026.05.010_bib0026","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.cllc.2024.02.006","article-title":"Durvalumab consolidation after chemoradiotherapy in elderly patients with unresectable stage III NSCLC: a real-world multicenter study","volume":"25","author":"Park","year":"2024","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2026.05.010_bib0027","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.cllc.2024.07.001","article-title":"Real-world efficacy and safety of durvalumab administration following chemoradiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer: a multicenter, retrospective study","volume":"25","author":"Kakiuchi","year":"2024","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2026.05.010_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2024.101705","article-title":"Real world efficacy and toxicity of consolidation durvalumab following chemoradiotherapy in older Australian patients with unresectable stage III non-small cell lung cancer","volume":"15","author":"Stevens","year":"2024","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.cllc.2026.05.010_bib0029","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17152498","article-title":"Real-world outcomes of chemoradiotherapy in patients with stage II\/III non-small-cell lung cancer in the durvalumab era: an observational study","volume":"17","author":"M\u00fcller","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.cllc.2026.05.010_bib0030","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1177\/0300891620971359","article-title":"Lower lobe origin is related to unfavorable outcomes in patients with stage I-III lung cancer treated with radical chemoradiotherapy","volume":"107","author":"Liu","year":"2021","journal-title":"Tumori"},{"key":"10.1016\/j.cllc.2026.05.010_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2022.109454","article-title":"Impact of interstitial lung abnormality on survival after adjuvant durvalumab with chemoradiotherapy for locally advanced non-small cell lung cancer","volume":"180","author":"Kashihara","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.cllc.2026.05.010_bib0032","article-title":"Predictors of pneumonitis in patients with locally advanced non-small cell lung cancer treated with definitive chemoradiation followed by consolidative durvalumab","volume":"8","author":"Diamond","year":"2023","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.cllc.2026.05.010_bib0033","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1002\/cam4.3093","article-title":"Radiation pneumonitis after definitive concurrent chemoradiotherapy with cisplatin\/docetaxel for non-small cell lung cancer: analysis of dose-volume parameters","volume":"9","author":"Katsui","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.cllc.2026.05.010_bib0034","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.radonc.2021.05.016","article-title":"Intensity-modulated radiation therapy with concurrent chemotherapy followed by durvalumab for stage III non-small cell lung cancer: a multi-center retrospective study","volume":"160","author":"Tsukita","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.cllc.2026.05.010_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108578","article-title":"Impact of durvalumab re-administration after moderate symptomatic pneumonitis in locally advanced non-small cell lung cancer","volume":"204","author":"Kakiuchi","year":"2025","journal-title":"Lung Cancer"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426000781?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426000781?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T21:26:26Z","timestamp":1785878786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730426000781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1525730426000781"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2026.05.010","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Durvalumab After Chemoradiotherapy for Locally Advanced NSCLC: A Real-World Analysis Using a Nationwide Claims Database in Japan","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2026.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}